Back to Top Skip to main content Skip to sub-navigation

Defending the Homeland: Turning on lifesaving trials at Madigan Army Medical Center

Image of soldier in front of a laptop Janell Cain, a clinical research coordinator at Madigan with the Infectious Disease Clinical Research Program, records the informed consent forms signed by a patient receiving treatment for COVID-19 in the intensive care unit from Madigan’s Virtual Critical Care Center on April 14. Communicating with the patient and nurses via the video equipment, Cain gains the necessary consent to enroll a patient in a study of remdesivir as a COVID-19 treatment without expending personal protective equipment, or exposing anyone to the patient unnecessarily. The IDCRP is a Department of Defense-wide research consortium headquartered at the Uniformed Services University for the Health Sciences in Bethesda, Md. (Lt. Col. (Dr.) Christopher Colombo)

Recommended Content:

Coronavirus

MADIGAN ARMY MEDICAL CENTER, Joint Base Lewis-McChord, Wash. – Madigan Army Medical Center, on Joint Base Lewis-McChord, Wash., has been a hotbed for biomedical research for years, highlighted by patented innovations and award winning presentations at national and international scientific meetings.

In response to the COVID-19 global pandemic, Madigan is currently supporting nine research protocols designed to address gaps in knowledge including clinical characteristics of the COVID-19 illness, the impact of nutrition on COVID-19 risk, and the clinical value of convalescent plasma, in which a patient with severe disease is given plasma from someone who has recovered from COVID-19 and therefore has antibodies to it in their blood, to name a few.

Possibly the most notable clinical trial for COVID-19 treatment involves remdesivir, an investigational, broad-spectrum antiviral drug that has shown some promise, in animal trials, in both Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS), which are caused by other coronaviruses.

The trial is sponsored by the National Institute of Allergy and Infectious Diseases, which is part of the National Institutes of Health, and is the first clinical trial in the U.S. to evaluate an experimental treatment for COVID-19.

When the trial began in February, Dr. Anthony Fauci, the director of NIAID and a member of the U.S. Coronavirus Task Force said, “We urgently need a safe and effective treatment for COVID-19. Although remdesivir has been administered to some patients with COVID-19, we do not have solid data to indicate it can improve clinical outcomes. A randomized, placebo-controlled trial is the gold standard for determining if an experimental treatment can benefit patients.”

Madigan is one of 68 international trial sites among 47 in the U.S. and 21 in Europe and Asia. The first enrollee was at the University of Nebraska Medical Center/Nebraska Medicine, in February; he had been on a cruise ship that saw a number of infections.

The initiation of the trial can is described here: https://www.niaid.nih.gov/news-events/nih-clinical-trial-remdesivir-treat-covid-19-begins.

Within two months of initiation, the clinical trial of remdesivir has produced encouraging results.

In a statement issued on April 29, the NIAID reported, “Preliminary results indicate that patients who received remdesivir had a 31 percent faster time to recovery than those who received placebo (p<0.001). Specifically, the median time to recovery was 11 days for patients treated with remdesivir compared with 15 days for those who received placebo. Results also suggested a survival benefit, with a mortality rate of 8.0 percent for the group receiving remdesivir versus 11.6 percent for the placebo group (p=0.059).”

This trial is managed at Madigan by the Infectious Disease Clinical Research Program, a Department of Defense-wide research consortium headquartered at the Uniformed Services University for the Health Sciences in Bethesda, Md. The IDCRP conducts clinical research that focuses on reducing the impact of infectious diseases relevant to the DoD.

For more information about the IDCRP, visit: https://www.idcrp.org/about-us.

The IDCRP has a broad research portfolio, including an ongoing study looking at the efficacy of different formulations of the flu vaccine. When COVID-19 emerged, the IDCRP pivoted to get this research up and running in a very short period of time. As an established IDCRP site, Madigan was identified as one of the military treatment facilities eligible for participation in the NIAID trial.

“Because they are so active and such a squared-away group, they were able to help get this trial off the ground,” said Lt. Col. (Dr.) Christopher Colombo, principal investigator for the COVID-19 trial and the director of Virtual Health and Telecritical Care at Madigan.

Madigan has strong and adaptive biomedical research capabilities that are facilitated by its Department of Clinical Investigation.

“The Department of Clinical Investigation, Dr. Rick Burney (DCI’s chief) and Dr. (Silvija) Salai (the human subject protection administrator), have been fantastic in supporting and expediting this and balancing making sure that everything is still done dress-right-dress according to regulatory, safety and scientific integrity filings, but it is going quite a bit faster than usual, because of the situation that we're in,” noted Lt. Col. Colombo.

Madigan is one of five DoD sites that has enrolled patients in the study so far and is already ramping up for its next phase. Investigators stress that these are early days of evaluation for this trial. Given the high transmissibility and global spread of this virus, research has moved quickly.

“It's a placebo controlled trial, so the patients are randomized. We don't know who's getting what. They either get placebo or remdesivir,” Lt. Col. Colombo said.

NIH requirements for inclusion in the trial comprise the need for hospitalization for documented COVID-19 infection and either an abnormal chest x-ray or the requirement for supplemental oxygen or mechanical ventilation. Trial participation is limited to adults.

Participants in the treatment group get 200 milligrams (mg) of remdesivir injected on the first day they are in the study and 100 mg each day of their hospitalization, up to 10 days total. Those in the placebo group receive the same amount of what looks like remdesivir but contains only inactive ingredients.

This means the trial is administered to patients currently being treated in the hospital, though some have since improved and gone home. They return to the hospital periodically for monitoring.

Dr. Rhonda Colombo, an infectious diseases physician who works in support of the IDCRP at Madigan, praised the contributions of patients who volunteered to participate in this and other ongoing clinical research trials.

“Without willing and engaged study participants, clinical research is not possible. At Madigan, we are incredibly fortunate to be part of a community that values clinical research. Our research team is humbled by the generosity and commitment of the people who volunteer to participate in our studies,” said Dr. Colombo.

With drug safety and long-term effects always in mind, the team is not yet ready to draw conclusions, but is optimistic about the data so far.

Susan Chambers, the clinical operations manager for the IDCRP at Madigan echoed that appreciation for the high value that Madigan, and the JBLM community place on research, noting that it is the providers and nurses on the inpatient units who directly support research within their care of patients.

“We are incredibly proud to have the opportunity to offer access to cutting-edge research for our Active Duty personnel and DoD beneficiaries. Our success would not be possible without the support of Madigan Commander Col. Thomas Bundt and the committed inpatient clinical care teams at Madigan,” said Chambers.

On Friday, May 1, the U.S. Food and Drug Administration gave remdesivir emergency use authorization to treat COVID-19.

The NIAID expects to share additional data soon, as well as next steps.

“We managed to get meaningful research turned on, very quickly. Other sites in the Department of Defense, are kind of looking at Madigan like you guys are knocking it out of the park, keep going,” said Lt. Col. Colombo. “I think it's something that's cool in terms of how we're responding to COVID in a positive way and making some good come of this.”

Disclaimer: Re-published content may be edited for length and clarity.  Read original post.

You also may be interested in...

From coast to coast, Navy personnel helping stop COVID-19 spread

Article
4/26/2021
Military personnel wearing face mask getting people ready for the COVID-19 vaccine

From coast to coast, Navy Medicine personnel are helping to stop the spread of COVID-19.

Recommended Content:

COVID-19 Vaccine Toolkit | COVID-19 Vaccine Toolkit | Coronavirus | COVID-19 Vaccine Efforts | COVID-19 Vaccine Toolkit

DHA’s immunization health care specialists support vaccine rollout

Article
4/26/2021
Military personnel getting COVID-19 vaccines ready

The Defense Health Agency’s Immunization Health Care Division specialists were instrumental in rolling out the COVID-19 vaccines to Department of Defense military medical treatment facilities around the world.

Recommended Content:

COVID-19 Vaccine Toolkit | COVID-19 Vaccine Toolkit | Coronavirus | COVID-19 Vaccine Efforts | COVID-19 Vaccine Toolkit

DHA Appointing Portal simplifies signing up for COVID-19 vaccination

Article
4/23/2021
Military health personnel wearing a face mask scheduling COVID-19 vaccine shots

A new online and easy-to-use COVID-19 vaccine appointment portal is rolling out around the world at Military Treatment Facilities. It needs some tweaking on the admin end, users say.

Recommended Content:

COVID-19 Vaccine Toolkit | COVID-19 Vaccine Toolkit | Coronavirus | COVID-19 Vaccine Efforts | Health Innovation Month

COVID-19 Vaccine: All Adults Eligible Graphic

Infographic
4/22/2021
A navy and gray graphic stating that all eligible and authorized DOD individuals can make a COVID vaccine appointment. Contains a QR code for individuals to use to sign up for an appointment. TRICARE logo is located at the bottom right corner.

Graphic stating that all eligible and authorized DOD individuals can make a COVID vaccine appointment. Contains sign up instructions.

Recommended Content:

COVID-19 Vaccine Toolkit | COVID-19 Vaccine Toolkit | Coronavirus

COVID-19 Vaccine: All Adults Eligible MTF Option Screensaver2

Infographic
4/22/2021
A screensaver that encourages individuals to check in at their DOD vaccination sites to see appointment availability. Includes the TRICARE logo on the bottom right and a link at the bottom of the screensaver for individuals to learn more at www.tricare.mil/VaccineAppointments

A screensaver that encourages individuals to check in at their DOD vaccination sites to see appointment availability.

Recommended Content:

COVID-19 Vaccine Toolkit | COVID-19 Vaccine Toolkit | Coronavirus

COVID-19 Vaccine: All Adults Eligible Choices Screensaver

Infographic
4/22/2021
A navy and gray graphic with information on where adults can get the COVID-19 vaccine. Includes a link at the bottom of the graphic for www.tricare.mil/CovidVaccine and also has the TRICARE logo on the bottom right corner.

A screensaver that provides information on where adults can get the COVID-19 vaccine.

Recommended Content:

COVID-19 Vaccine Toolkit | COVID-19 Vaccine Toolkit | Coronavirus

Laboratory professionals play important role in fight against COVID-19

Article
4/21/2021
Military health personnel wearing a face mask prepares COVID-19 test samples

Medical Laboratory Professionals Week, April 18-24, recognizes the behind-the-scenes work laboratorians do to generate clinical lab results and, ultimately, guide the courses of treatment for patients.

Recommended Content:

COVID-19 Vaccine Toolkit | MHS Toolkits and Branding Guidance | Coronavirus | COVID-19 Vaccine Efforts | April

Clinic doors open wide for those wanting COVID-19 vaccine

Article
4/21/2021
Military personnel administering the COVID-19 vaccine

All eligible and authorized Department of Defense personnel can now get a COVID-19 vaccine if they want one.

Recommended Content:

COVID-19 Vaccine Toolkit | COVID-19 Vaccine Toolkit | Coronavirus | COVID-19 Vaccine Efforts

Donate Blood: It's Mission Critical

Video
4/21/2021
DHA Seal

The pandemic has affected nearly every part of our lives, including reductions in blood donations. Find a military blood donor center today to donate blood in a safe environment where we take all precautions against COVID-19.

Recommended Content:

COVID-19 Vaccine Toolkit | Armed Services Blood Program | Coronavirus

From COVID-19 testing to MHS GENESIS support, lab techs do it all

Article
4/20/2021
Military health personnel wearing a face mask using a blood analyzer machine

To describe what lab techs do, Geisler chose a famed fictional detective to illustrate their importance and provide context.

Recommended Content:

MHS Toolkits and Branding Guidance | MHS Toolkits and Branding Guidance | Coronavirus | COVID-19 Vaccine Efforts

Tanker medics from McConnell AFB are fighting COVID-19 in St. Paul

Article
4/20/2021
Military health personnel wearing face masks hugging

Tanker Medics from McConnell Air Force Base travel to Minnesota to help fight COVID-19

Recommended Content:

MHS Toolkits and Branding Guidance | COVID-19 Vaccine Toolkit | Coronavirus | COVID-19 Vaccine Efforts

Keesler uses post-vaccine waiting period to identify routine care gaps

Article
4/20/2021
Military health personnel wearing a face mask administering the COVID-19 vaccine

15 minutes is all it takes to get routine health care back on track.

Recommended Content:

MHS Toolkits and Branding Guidance | MHS Toolkits and Branding Guidance | Coronavirus | COVID-19 Vaccine Efforts

VAX Fact Breastfeeding

Infographic
4/19/2021
VAX Fact Q and A: Can I get the COVID-19 vaccine if I'm breastfeeding? It's up to you to decide.  The CDC says COVID-19 vaccines can be offered to pregnant or breastfeeding women.  If you have questions about getting vaccinated, a conversation with your healthcare provider may help but is not required.

An infographic answering the question of whether you can get the COVID-19 vaccine if you're breastfeeding.

Recommended Content:

COVID-19 Vaccine Toolkit | COVID-19 Vaccine Toolkit | Coronavirus | COVID-19 Vaccine Efforts

VAX Fact Other Medical Conditions

Infographic
4/19/2021
VAX Fact: Can I get a COVID-19 vaccine if I have other medical conditions? If you have underlying medical conditions, you can choose a COVID-19 vaccine if you have not had an immediate or severe allergic reaction to any ingredients in the shots. Vaccination is an important consideration for adults of any age to reduce risk of severe illness from COVID-19.

An infographic answering the question of whether you can get the COVID-19 vaccine if you have underlying medical conditions.

Recommended Content:

COVID-19 Vaccine Toolkit | COVID-19 Vaccine Toolkit | Coronavirus | COVID-19 Vaccine Efforts

VAX Fact Protection Last

Infographic
4/19/2021
VAX Fact: How long does a COVID-19 vaccine protect me for? We do not know yet how long protection may last for those who receive a COVID-19 vaccine.  We do know a COVID-19 vaccine may reduce your chances of spreading the illness to others or facing more serious illness, including hospitalization. Getting a COVID-19 vaccine is a safer choice.

An infographic answering the question of how long the COVID-19 vaccine protection lasts.

Recommended Content:

COVID-19 Vaccine Toolkit | COVID-19 Vaccine Toolkit | Coronavirus | COVID-19 Vaccine Efforts
<< < ... 6 7 8 9 10  ... > >> 
Showing results 76 - 90 Page 6 of 35

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.